Advisory: Alert on Otsuka Pharmaceutical wrongly tagged to Otsuka Corp withdrawn
04/06/2026 19:53
ADVISORY-Alert on Otsuka Pharmaceutical wrongly tagged to Otsuka Corp withdrawn An alert on Otsuka Pharmaceutical's 4578.T kidney disease drug was inadvertently tagged to Otsuka Corp 4768.T, an unrelated company, and has been withdrawn. For the correctly coded alerts, click nFWN42C0QE.
STORY_NUMBER: nFWN42C0UT
STORY_DATE: June 4, 2026
STORY_TIME: 06:32 PM GMT
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug